HBM Holdings Says NMPA Accepts IND Application For HBM7004 For Advanced Solid Tumors - TradingView

www.tradingview.com 2026-06-10 TradingView

Entities

Technologies:HBM7004 immunotherapy bispecific antibody

Tags

Oncology Drug Development IND Application NMPA HBM7004 Biopharma Innovation Drug Clinical Trial Cancer Immunotherapy Regulatory Approval FDA Drug Approval

News Summary

HBM Holdings announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for its novel cancer immunotherapy drug HBM7004, in... Read original →

Read Original Article →

This page displays AI-generated summaries and metadata for research purposes. Original content belongs to the respective publishers.